Publication: Clinical outcomes based on measurable residual disease status in patients with core-binding factor acute myeloid leukemia: A systematic review and meta-analysis
Issued Date
2020-11-01
Resource Type
ISSN
20754426
Other identifier(s)
2-s2.0-85096646804
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Personalized Medicine. Vol.10, No.4 (2020), 1-12
Suggested Citation
Wannaphorn Rotchanapanya, Peter Hokland, Pattaraporn Tunsing, Weerapat Owattanapanich Clinical outcomes based on measurable residual disease status in patients with core-binding factor acute myeloid leukemia: A systematic review and meta-analysis. Journal of Personalized Medicine. Vol.10, No.4 (2020), 1-12. doi:10.3390/jpm10040250 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/60571
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Clinical outcomes based on measurable residual disease status in patients with core-binding factor acute myeloid leukemia: A systematic review and meta-analysis
Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Measurable residual disease (MRD) response during acute myeloid leukemia (AML) treatment is a gold standard for determining treatment strategy, especially in core-binding factor (CBL) AML. The aim of this study was to critically review the literature on MRD status in the CBF-AML to determine the overall impact of MRD status on clinical outcomes. Published studies in the MEDLINE and EMBASE databases from their inception up to 1 June 2019 were searched. The primary end-point was either overall survival (OS) or recurrence-free survival (RFS) between MRD negative and MRD positive CBF-AML patients. The secondary variable was cumulative incidence of relapse (CIR) between groups. Of the 736 articles, 13 relevant studies were included in this meta-analysis. The MRD negative group displayed more favorable recurrence-free survival (RFS) than those with MRD positivity, with a pooled odds ratio (OR) of 4.5. Moreover, OS was also superior in the MRD negative group, with a pooled OR of 7.88. Corroborating this, the CIR was statistically significantly lower in the MRD negative group, with a pooled OR of 0.06. The most common cutoff MRD level was 1 × 10−3. These results suggest that MRD assessment should be a routine investigation in clinical practice in this AML subset.